In vitro production of specific antibody by equine peripheral blood mononuclear cells using tetanus toxoid as a recall antigen.

The research article investigates the optimal conditions for the in vitro production of anti-tetanus toxin (TT) antibodies by horse immune cells, using certain concentrations of the tetanus toxoid and specific cell concentrations.

Study Explanation

This study involved using immune cells known as peripheral blood mononuclear cells (PBMC) from horses that had been pre-exposed to tetanus toxoid (TT). The toxoid is treated form of tetanus toxin, commonly used for tetanus immunization. The researchers measured levels of anti-TT antibodies in the cell culture supernatant using an indirect ELISA method. The specifics of the study include:

• They discovered that the best antibody production occurred when the TT concentration was between 0.001 and 0.1 micrograms ml-1. The exact optimal concentration depended on the cell concentration used.
• Most consistent and optimal antibody production was achieved when the cell concentration was at 5 x 10(6) ml-1. The maximal levels of antibodies were produced at a concentration of 0.1 micrograms ml-1 TT at this cell concentration.
• Under these optimal conditions, the antibody production was first observable on the 5th day of stimulation and reached the highest level by the 10th day. This timeline provides important details for future experiments involving equine anti-TT antibody production.
• No antibody production was observed in cell cultures from horses that hadn’t been exposed to TT, establishing the crucial role of prior exposure to the tetanus toxoid in this particular antibody production process.

Accordingly, this study contributes substantial knowledge in relation to equine antibody production against the tetanus toxin in vitro. The derived information could be useful for vaccine manufacturing as well as for various immunology and infected therapy related research studies involving horses.